The ongoing Bundibugyo virus outbreak in the Democratic Republic of the Congo, declared in May 2026 and now the country's deadliest with over 5,500 confirmed cases and 2,600 deaths across multiple provinces, dominates trader sentiment as the clear frontrunner. Rapid geographic expansion, insecurity, and high mobility have driven spread, including 20 cases in Uganda—where transmission ended by late July—and one imported case in France. Neighboring countries like South Sudan, Rwanda, and Burundi face elevated risk through cross-border movement but report zero cases amid heightened surveillance. With the outbreak still active and no licensed vaccine for this strain, momentum hinges on containment success versus further regional jumps before year-end.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedWhich countries will have an Ebola case in 2026?
Which countries will have an Ebola case in 2026?
$34,886 Vol.
Dec 30, 2026
South Sudan
62%
Rwanda
28%
Burundi
29%
United States
23%
Canada
24%
Kenya
38%
India
14%
Republic of the Congo
26%
Nigeria
16%
Ethiopia
49%
Somalia
34%
China
13%
$34,886 Vol.
South Sudan
$2,171 Vol.
62%
Rwanda
$2,128 Vol.
28%
Burundi
$200 Vol.
29%
United States
$10,215 Vol.
23%
Canada
$1,366 Vol.
24%
Kenya
$235 Vol.
38%
India
$732 Vol.
14%
Republic of the Congo
$12,170 Vol.
26%
Nigeria
$25 Vol.
16%
Ethiopia
$107 Vol.
49%
Somalia
$71 Vol.
34%
China
$3,512 Vol.
13%
This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.The ongoing Bundibugyo virus outbreak in the Democratic Republic of the Congo, declared in May 2026 and now the country's deadliest with over 5,500 confirmed cases and 2,600 deaths across multiple provinces, dominates trader sentiment as the clear frontrunner. Rapid geographic expansion, insecurity, and high mobility have driven spread, including 20 cases in Uganda—where transmission ended by late July—and one imported case in France. Neighboring countries like South Sudan, Rwanda, and Burundi face elevated risk through cross-border movement but report zero cases amid heightened surveillance. With the outbreak still active and no licensed vaccine for this strain, momentum hinges on containment success versus further regional jumps before year-end.
This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Market Opened: May 22, 2026, 12:35 PM ET
Volume
$34,886End Date
Dec 31, 2026Market Opened
May 22, 2026, 12:35 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.The ongoing Bundibugyo virus outbreak in the Democratic Republic of the Congo, declared in May 2026 and now the country's deadliest with over 5,500 confirmed cases and 2,600 deaths across multiple provinces, dominates trader sentiment as the clear frontrunner. Rapid geographic expansion, insecurity, and high mobility have driven spread, including 20 cases in Uganda—where transmission ended by late July—and one imported case in France. Neighboring countries like South Sudan, Rwanda, and Burundi face elevated risk through cross-border movement but report zero cases amid heightened surveillance. With the outbreak still active and no licensed vaccine for this strain, momentum hinges on containment success versus further regional jumps before year-end.
This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Volume
$34,886End Date
Dec 31, 2026Market Opened
May 22, 2026, 12:35 PM ETResolver
0x65070BE91...The ongoing Bundibugyo virus outbreak in the Democratic Republic of the Congo, declared in May 2026 and now the country's deadliest with over 5,500 confirmed cases and 2,600 deaths across multiple provinces, dominates trader sentiment as the clear frontrunner. Rapid geographic expansion, insecurity, and high mobility have driven spread, including 20 cases in Uganda—where transmission ended by late July—and one imported case in France. Neighboring countries like South Sudan, Rwanda, and Burundi face elevated risk through cross-border movement but report zero cases amid heightened surveillance. With the outbreak still active and no licensed vaccine for this strain, momentum hinges on containment success versus further regional jumps before year-end.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions